Anoctamin-5 related muscle disease : clinical and genetic findings in a large European cohort
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Anoctamin-5 related muscle disease is caused by biallelic pathogenic variants in the anoctamin-5 gene (ANO5) and shows variable clinical phenotypes: limb-girdle muscular dystrophy type 12 (LGMD-R12), distal muscular dystrophy type 3 (MMD3), pseudometabolic myopathy or asymptomatic hyperCKaemia. In this retrospective, observational, multicentre study we gathered a large European cohort of patients with ANO5-related muscle disease to study the clinical and genetic spectrum and genotype-phenotype correlations. We included 234 patients from 212 different families, contributed by 15 centres from 11 European countries. The largest subgroup was LGMD-R12 (52.6%), followed by pseudometabolic myopathy (20.5%), asymptomatic hyperCKaemia (13.7%) and MMD3 (13.2%). In all subgroups, there was a male predominance, except for pseudometabolic myopathy. Median age at symptom onset of all patients was 33 years (range 23-45 years). The most frequent symptoms at onset were myalgia (35.3%) and exercise intolerance (34.1%), while at last clinical evaluation most frequent symptoms and signs were proximal lower limb weakness (56.9%) and atrophy (38.1%), myalgia (45.1%) and atrophy of the medial gastrocnemius muscle (38.4%). Most patients remained ambulatory (79.4%). At last evaluation, 45.9% of patients with LGMD-R12 additionally had distal weakness in the lower limbs and 48.4% of patients with MMD3 also showed proximal lower limb weakness. Age at symptom onset did not differ significantly between males and females. However, males had a higher risk of using walking aids earlier (P = 0.035). No significant association was identified between sportive versus non-sportive lifestyle before symptom onset and age at symptom onset nor any of the motor outcomes. Cardiac and respiratory involvement that would require treatment occurred very rarely. Ninety-nine different pathogenic variants were identified in ANO5 of which 25 were novel. The most frequent variants were c.191dupA (p.Asn64Lysfs*15) (57.7%) and c.2272C>T (p.Arg758Cys) (11.1%). Patients with two loss-of function variants used walking aids at a significantly earlier age (P = 0.037). Patients homozygous for the c.2272C>T variant showed a later use of walking aids compared to patients with other variants (P = 0.043). We conclude that there was no correlation of the clinical phenotype with the specific genetic variants, and that LGMD-R12 and MMD3 predominantly affect males who have a significantly worse motor outcome. Our study provides useful information for clinical follow up of the patients and for the design of clinical trials with novel therapeutic agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Brain : a journal of neurology - 146(2023), 9 vom: 01. Sept., Seite 3800-3815 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
ANO5 protein, human |
|---|
| Anmerkungen: |
Date Completed 04.09.2023 Date Revised 07.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/brain/awad088 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354188593 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354188593 | ||
| 003 | DE-627 | ||
| 005 | 20231226061700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/brain/awad088 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354188593 | ||
| 035 | |a (NLM)36913258 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Bruyn, Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anoctamin-5 related muscle disease |b clinical and genetic findings in a large European cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2023 | ||
| 500 | |a Date Revised 07.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Anoctamin-5 related muscle disease is caused by biallelic pathogenic variants in the anoctamin-5 gene (ANO5) and shows variable clinical phenotypes: limb-girdle muscular dystrophy type 12 (LGMD-R12), distal muscular dystrophy type 3 (MMD3), pseudometabolic myopathy or asymptomatic hyperCKaemia. In this retrospective, observational, multicentre study we gathered a large European cohort of patients with ANO5-related muscle disease to study the clinical and genetic spectrum and genotype-phenotype correlations. We included 234 patients from 212 different families, contributed by 15 centres from 11 European countries. The largest subgroup was LGMD-R12 (52.6%), followed by pseudometabolic myopathy (20.5%), asymptomatic hyperCKaemia (13.7%) and MMD3 (13.2%). In all subgroups, there was a male predominance, except for pseudometabolic myopathy. Median age at symptom onset of all patients was 33 years (range 23-45 years). The most frequent symptoms at onset were myalgia (35.3%) and exercise intolerance (34.1%), while at last clinical evaluation most frequent symptoms and signs were proximal lower limb weakness (56.9%) and atrophy (38.1%), myalgia (45.1%) and atrophy of the medial gastrocnemius muscle (38.4%). Most patients remained ambulatory (79.4%). At last evaluation, 45.9% of patients with LGMD-R12 additionally had distal weakness in the lower limbs and 48.4% of patients with MMD3 also showed proximal lower limb weakness. Age at symptom onset did not differ significantly between males and females. However, males had a higher risk of using walking aids earlier (P = 0.035). No significant association was identified between sportive versus non-sportive lifestyle before symptom onset and age at symptom onset nor any of the motor outcomes. Cardiac and respiratory involvement that would require treatment occurred very rarely. Ninety-nine different pathogenic variants were identified in ANO5 of which 25 were novel. The most frequent variants were c.191dupA (p.Asn64Lysfs*15) (57.7%) and c.2272C>T (p.Arg758Cys) (11.1%). Patients with two loss-of function variants used walking aids at a significantly earlier age (P = 0.037). Patients homozygous for the c.2272C>T variant showed a later use of walking aids compared to patients with other variants (P = 0.043). We conclude that there was no correlation of the clinical phenotype with the specific genetic variants, and that LGMD-R12 and MMD3 predominantly affect males who have a significantly worse motor outcome. Our study provides useful information for clinical follow up of the patients and for the design of clinical trials with novel therapeutic agents | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anoctaminopathy | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a natural history | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Anoctamins |2 NLM | |
| 650 | 7 | |a ANO5 protein, human |2 NLM | |
| 700 | 1 | |a Montagnese, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Holm-Yildiz, Sonja |e verfasserin |4 aut | |
| 700 | 1 | |a Scharff Poulsen, Nanna |e verfasserin |4 aut | |
| 700 | 1 | |a Stojkovic, Tanya |e verfasserin |4 aut | |
| 700 | 1 | |a Behin, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Palmio, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Jokela, Manu |e verfasserin |4 aut | |
| 700 | 1 | |a De Bleecker, Jan L |e verfasserin |4 aut | |
| 700 | 1 | |a de Visser, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a van der Kooi, Anneke J |e verfasserin |4 aut | |
| 700 | 1 | |a Ten Dam, Leroy |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez González, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Maggi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Gallone, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Kostera-Pruszczyk, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Macias, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Łusakowska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Nedkova, Velina |e verfasserin |4 aut | |
| 700 | 1 | |a Olive, Montse |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Velasco, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Wanschitz, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Paradas, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Mavillard, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Querin, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Eulate, Gorka |e verfasserin |4 aut | |
| 700 | 1 | |a Quinlivan, Ros |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Maggie C |e verfasserin |4 aut | |
| 700 | 1 | |a Depuydt, Christophe E |e verfasserin |4 aut | |
| 700 | 1 | |a Udd, Bjarne |e verfasserin |4 aut | |
| 700 | 1 | |a Vissing, John |e verfasserin |4 aut | |
| 700 | 1 | |a Schoser, Benedikt |e verfasserin |4 aut | |
| 700 | 1 | |a Claeys, Kristl G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain : a journal of neurology |d 1945 |g 146(2023), 9 vom: 01. Sept., Seite 3800-3815 |w (DE-627)NLM000126292 |x 1460-2156 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:3800-3815 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/brain/awad088 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2023 |e 9 |b 01 |c 09 |h 3800-3815 | ||